Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020293 citationsJournal Article

Authors

Max S. Topp · Universitätsklinikum Würzburg

Johannes Duell · Universitätsklinikum Würzburg

Gerhard Zugmaier · Amgen (Germany)

Michel Attal · Université de Toulouse

Philippe Moreau

Christian Langer · Kempten University of Applied Sciences

Jan Krönke · Universität Ulm

Abstract

In this study of AMG 420 in patients with relapsed/refractory multiple myeloma, the response rate was 70%, including 50% MRD-negative complete responses, at 400 μg/d, the MTD for this study.

Topics & Keywords

Multiple Myeloma Research and Treatments CAR-T cell therapy research Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 8, pp. 775-783

DOI: 10.1200/jco.19.02657

Field-Weighted Citation Impact: 29.30